Electrostatic Dissipative Feature Augments New Line of Ductless Fume Hoods
By LabMedica International staff writers Posted on 13 Aug 2013 |
Image: Aura ESD ductless fume hoods are self-contained, filtered enclosures that remove hazardous fumes, vapors and particles from virtually any laboratory application. Unlike traditional fume hoods, there are no installation costs and no ductwork is needed (Photo courtesy of Mystaire Misonix).
Image: Aura - how it works: Laboratory air enters Aura at ″A″ and is combined with contaminated air at ″B″ before entering into filtration at ″C.″ Filtration at ″C″ can be gas phase, mechanical, or both depending on the application. At ″D,″ air is pulled into the plenum area. The gas detector and test port sampling tubing are located in this area. At ″E,″ optional safety filtration can be installed before contaminant-free air is returned to the laboratory space at ″F″ (Photo courtesy of Mystaire Misonix).
A new line of fume hoods that promises laboratory workers superior protection against buildup of toxic fumes has been combined with electrostatic dissipative features to prevent static buildup and discharge.
Aura ductless fume hoods manufactured by Mystaire Misonix (Creedmoor, NC, USA) are self-contained, filtered enclosures that remove hazardous fumes, vapors, and particles from virtually any laboratory application. Unlike traditional fume hoods, there are no installation costs and no ductwork is needed. The new Aura ESD line of hoods adds an electrostatic dissipation feature to the state-of-the art Aura line.
Each Aura ductless fume hood has advanced safety monitoring and controls including the EverSafe II microprocessor safety controller, which monitors and adjusts fume hood face velocity to a user-preset value. EverSafe II maintains face velocity at the proper rate for containment of potentially toxic gases and vapors.
The US made Aura fume hoods, which are available in 72.6 centimeter, 106.68 centimeter, and 137.16-centimeter widths have been ASHRAE (American Society of Heating, Refrigerating and Air Conditioning Engineers) 110 tested and provide excellent containment from toxic fumes and vapors. The Filtrak positive filter sealing system installed in each Aura ductless hood is a cam-driven filter sealing system with a built-in filter position indicator and an alert that informs the user if the filtration bed is not properly sealed. The Filtrak system enables safe and easy filter maintenance and replacement.
Related Links:
Mystaire Misonix
Aura ductless fume hoods manufactured by Mystaire Misonix (Creedmoor, NC, USA) are self-contained, filtered enclosures that remove hazardous fumes, vapors, and particles from virtually any laboratory application. Unlike traditional fume hoods, there are no installation costs and no ductwork is needed. The new Aura ESD line of hoods adds an electrostatic dissipation feature to the state-of-the art Aura line.
Each Aura ductless fume hood has advanced safety monitoring and controls including the EverSafe II microprocessor safety controller, which monitors and adjusts fume hood face velocity to a user-preset value. EverSafe II maintains face velocity at the proper rate for containment of potentially toxic gases and vapors.
The US made Aura fume hoods, which are available in 72.6 centimeter, 106.68 centimeter, and 137.16-centimeter widths have been ASHRAE (American Society of Heating, Refrigerating and Air Conditioning Engineers) 110 tested and provide excellent containment from toxic fumes and vapors. The Filtrak positive filter sealing system installed in each Aura ductless hood is a cam-driven filter sealing system with a built-in filter position indicator and an alert that informs the user if the filtration bed is not properly sealed. The Filtrak system enables safe and easy filter maintenance and replacement.
Related Links:
Mystaire Misonix
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples